Oncimmune Holdings Past Earnings Performance
Past criteria checks 0/6
Oncimmune Holdings has been growing earnings at an average annual rate of 11%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 20.4% per year.
Key information
11.0%
Earnings growth rate
22.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 20.4% |
| Return on equity | n/a |
| Net Margin | -258.6% |
| Last Earnings Update | 29 Feb 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Oncimmune Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 1 | -3 | 2 | 1 |
| 30 Nov 23 | 1 | -5 | 3 | 1 |
| 31 Aug 23 | 1 | -6 | 4 | 1 |
| 31 Aug 22 | 2 | -5 | 5 | 1 |
| 31 May 22 | 3 | -10 | 9 | 2 |
| 28 Feb 22 | 4 | -8 | 8 | 2 |
| 30 Nov 21 | 3 | -7 | 8 | 2 |
| 31 Aug 21 | 4 | -6 | 8 | 2 |
| 31 May 21 | 4 | -5 | 7 | 2 |
| 28 Feb 21 | 3 | -5 | 7 | 1 |
| 30 Nov 20 | 2 | -6 | 7 | 1 |
| 31 Aug 20 | 1 | -7 | 7 | 1 |
| 31 May 20 | 1 | -8 | 8 | 2 |
| 29 Feb 20 | 0 | -9 | 8 | 2 |
| 30 Nov 19 | 0 | -9 | 9 | 2 |
| 31 Aug 19 | 0 | -9 | 7 | 2 |
| 31 May 19 | 0 | -8 | 6 | 2 |
| 28 Feb 19 | 0 | -8 | 6 | 1 |
| 30 Nov 18 | 0 | -7 | 6 | 1 |
| 31 Aug 18 | 0 | -7 | 5 | 1 |
| 31 May 18 | 0 | -6 | 5 | 1 |
| 28 Feb 18 | 0 | -6 | 4 | 1 |
| 30 Nov 17 | 0 | -5 | 4 | 1 |
| 31 Aug 17 | 0 | -5 | 4 | 1 |
| 31 May 17 | 0 | -5 | 4 | 1 |
| 28 Feb 17 | 0 | -8 | 4 | 1 |
| 30 Nov 16 | 0 | -10 | 4 | 1 |
| 31 Aug 16 | 0 | -9 | 4 | 1 |
| 31 May 16 | 0 | -8 | 4 | 1 |
| 31 May 15 | 1 | -2 | 2 | 1 |
| 31 May 14 | 1 | -1 | 3 | 0 |
Quality Earnings: ONC is currently unprofitable.
Growing Profit Margin: ONC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONC is unprofitable, but has reduced losses over the past 5 years at a rate of 11% per year.
Accelerating Growth: Unable to compare ONC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.8%).
Return on Equity
High ROE: ONC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.